A PHASE 3B, SINGLE-CENTER, OPEN-LABEL STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE WHEN ADMINISTERED AT A 0, 2-MONTH SCHEDULE IN HEALTHY AT-RISK ADULTS AGED 18 TO 65 YEARS INCLUSIVE.: